Milestone Pharmaceuticals Files 8-K on Financials
Ticker: MIST · Form: 8-K · Filed: Mar 13, 2025 · CIK: 1408443
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Milestone Pharma dropped an 8-K on March 13th about their financials. Check it for the latest.
AI Summary
Milestone Pharmaceuticals Inc. filed an 8-K on March 13, 2025, reporting on its results of operations and financial condition. The filing details the company's financial statements and exhibits, providing an update on its current status. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing provides an update on Milestone Pharmaceuticals' financial condition, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial reporting and does not indicate any immediate or significant risks.
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Registrant
- March 13, 2025 (date) — Date of Report
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details are not provided in the excerpt.
What is the exact date of the earliest event reported?
The date of the earliest event reported is March 13, 2025.
Where is Milestone Pharmaceuticals Inc. headquartered?
Milestone Pharmaceuticals Inc. is headquartered in Montreal, Quebec, Canada, at 1111 Dr. Frederik-Philips Boulevard, Suite 420.
What is the Commission File Number for Milestone Pharmaceuticals Inc.?
The Commission File Number for Milestone Pharmaceuticals Inc. is 001-38899.
What is the Standard Industrial Classification (SIC) code for Milestone Pharmaceuticals Inc.?
The Standard Industrial Classification code for Milestone Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 13, 2025 regarding Milestone Pharmaceuticals Inc. (MIST).